Reduction in membranous expression of β-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer by Ramesh, S et al.
Despite a steady decline in incidence, gastric carcinoma remains
the second most common lethal malignancy worldwide (Whelan
et al, 1993), and causes 10 000 deaths per year in England and
Wales (Cancer Research Council Factsheet 18). Infection with
Helicobacter pylori has been strongly implicated in its patho-
genesis (Eurogast Study Group, 1993), as have dietary factors
(Buiatti et al, 1989), but the molecular mechanisms underlying its
development remain relatively poorly understood. Numerous
abnormalities of expression have been reported in molecules
modulating growth and cell division such as tyrosine kinase
growth factor receptors (Tahara et al, 1986), p53 and other apop-
tosis-related genes (Hollstein et al, 1991) and more recently genes
controlling intercellular adhesion, such as E-cadherin and related
molecules. Numerous reports now indicate a role for disruption of
the cadherin–catenin complex in a variety of human cancers
(Bringuier et al, 1993; Oka et al, 1993; Pignatelli et al, 1994;
Krishnadath et al, 1997). Experimental studies suggest an impor-
tant permissive role for loss of cadherin complex function in inva-
sion and metastasis (Takeichi, 1993; Birchmeier et al, 1994). Links
have been revealed between the E-cadherin–catenin complex and
intracellular signalling pathways involving the tumour suppressor
gene APC (Rubinfeld et al, 1993; Munemitsu et al, 1995) and
the oncogene wnt-1 (Papkoff et al, 1996; Korinek et al, 1997).
More recent work has confirmed that tyrosine phosphorylation of
b-catenin may participate in regulation of the cadherin–catenin
complex in vivo (Takayama et al, 1998). Abnormal expression of
each of the main components of the complex (E-cadherin, a-,
b-catenin and plakoglobin) have been demonstrated in gastric
cancer, and are commoner in the diffuse, poorly differentiated
than in the intestinal, more well-differentiated histological type
(Jawahari et al, 1997). Reduced expression of b-catenin has been
shown to be an independent predictor of poor prognosis in gastric
cancer (Jawahari et al, 1997), but the nature of the expression
abnormalities, and their specific associations with survival have
not been adequately evaluated. In colorectal cancer, increased
cytoplasmic and nuclear staining is an independent predictor of
poor survival (Hugh et al, 1999), whereas loss of expression at the
cell membrane is not. In the mouse model of familial adenomatous
polyposis, cytoplasmic accumulation of b-catenin occurs in the
premalignant stage of the adenoma:carcinoma sequence enabling
genes associated with neoplastic growth to be overexpressed
(Clark et al, 1999). Cytoplasmic and nuclear accumulation of b-
catenin are known to result from loss-of-function mutations of the
APC gene (Munemitsu et al, 1995), which are common in sporadic
colorectal cancer, but less frequent in gastric cancer (Nakatsuru et
al, 1992; Powell et al, 1992). It therefore seems that abnormalities
of b-catenin expression in gastric cancer may arise by different
mechanisms. Detailed study of the expression of b-catenin and
other members of the cadherin/catenin complex, and their associa-
tion with outcome, may therefore yield useful insights into the
mechanisms of development and progression of both gastric and
colorectal cancer.
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Summary b-catenin, a component of the E-cadherin–catenin cell adhesion complex, also plays a separate intracellular signalling role,
interacting with APC protein. Intracellular accumulation of b-catenin is common in colorectal neoplasia. b-catenin abnormalities are
associated with poor survival in gastric cancer, but previous studies do not differentiate between membrane-associated and intracellular
b-catenin. In this study we aimed to determine which type of expression abnormalities for E-cadherin, b-catenin and a-catenin correlate with
clinico-pathological features and survival in gastric cancer. Immunoperoxidase staining of paraffin-embedded sections from 40 gastric
cancers was performed for E-cadherin, a- and b-catenins using microwave unmasking and an avidin–biotin technique. Clinical data were
obtained from case records and cancer registry records. Reduced membranous expression of b-catenin occurred in 10/12 (83%) diffuse and
8/28 (29%) intestinal tumours (P = 0.0014), and was associated with poor differentiation (P = 0.0015) and short survival (P = 0.032), but not
with age, sex, tumour size or nodal status. Nuclear expression of b-catenin was uncommon; cytoplasmic expression was observed in 13/40
cases (33%) but did not correlate with histology, tumour grade or survival. Reduced E-cadherin membrane expression was associated with
lymph node metastasis (P = 0.02). Neither E-cadherin or a-catenin expression correlated with survival. Reduced membranous expression of
b-catenin predicts poor prognosis in gastric cancer, whilst ectopic intracellular expression is relatively rare. The apparent differences in
b-catenin expression from those found in colon cancer merit further study. © 1999 Cancer Research Campaign
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MATERIALS AND METHODS
Tumour specimens
Formalin-fixed, paraffin-embedded gastric carcinoma tissue
samples were obtained from 48 consecutive patients undergoing
partial or total gastrectomy for gastric carcinoma between 1992
and 1995 from the archival tissue of the Pathology Department at
Aintree NHS Trust. Adjacent non-involved gastric mucosa was
obtained from all cases. Of the 48 patients identified, 40 were
considered suitable for analysis (31 male patients, median age
68 years, range 57–87 years). Five cases were deemed ineligible
because follow-up data was unavailable (two patients had moved
out of the region, three had died from early post-operative compli-
cations) and suitable well preserved blocks could not be obtained
in three cases. Tumours were classified using the Lauren system
(Lauren, 1965) into intestinal and diffuse types. Intestinal type
tumours were graded into well, moderately or poorly differentiated
according to the predominant pattern of the tumour. Tumours were
staged using the criteria for TNM evaluation of the unified inter-
national gastric cancer staging classification (Maruyama and
Miwa, 1987).
Clinical details
Clinico-pathological information and survival data were obtained
from hospital records, contact with general practitioners and the
Cancer Registry office. The data collected in each case is shown in
Table 1.
Antibodies (monoclonal)
Mouse monoclonal immunoglobulin (Ig)G antibody to E-cadherin
(HECD 1) was purchased from R&D Systems Europe, Abingdon,
UK. Anti-b-catenin monoclonal IgG antibody, and anti-a-catenin
monoclonal antibody were bought from Affinity Research
Products Ltd (Exeter, UK). Final antibody dilutions, determined
by serial dilutions against positive and negative controls, were:
anti-E-cadherin 1:100, anti-b-catenin 1:75 and anti-a-catenin
1:20.
Immunostaining
Five-micrometre sections were cut from formalin-fixed, paraffin-
embedded tissue blocks for haematoxylin and eosin (H&E) and
immunostaining. Consecutive slides for assessment of Lauren
class, grade and immunostaining were taken from the block
containing the greatest vertical depth of penetration of the gastric
wall by the tumour. Slides for evaluation of grade and Lauren class
were stained with H&E in conventional fashion. Sections for
immunohistochemical staining were mounted onto poly-L lysine-
coated slides.
A standard avidin–biotin immunoperoxidase technique was
used. Sections were dewaxed using xylene and transferred to
alcohol. Endogenous peroxidase activity was quenched by incuba-
tion in 3% hydrogen peroxide in methanol for 20 min. Antigen
retrieval was by microwaving for 15 min at 674 W in citrate buffer
at pH 6.0. Non-specific binding of secondary antibody was
blocked by incubating with 100 ml of fetal calf serum (FCS)
diluted to 1:20 for 10 min in a Shandon Sequenza tray (Shandon
Southern Ltd, UK). Incubation with primary antibody was at 37°C
for 120 min for anti-E-cadherin, 60 min at 37°C for anti-b-catenin,
and 4°C overnight for anti-a-catenin. After three washes with
Tris-buffered saline (TBS), the slides were incubated at room
temperature for 45 min with biotinylated secondary sheep anti-
mouse antibody (Amersham Life Science, Little Chalfont,
Buckinghamshire, UK) diluted 1:200 in TBS. Following three
further washings in TBS the slides were incubated with
avidin–biotin complex (ABC)/horseradish peroxidase solution
(Dako, UK) diluted to 1:100 with TBS. The slides were washed
further in TBS, and developed in activated 3,3-diaminobenzidine-
tetrahydrochloride containing 0.01% hydrogen peroxide for 8 min,
and the reaction stopped in water. The slides were counterstained
with haematoxylin and dehydrated in alcohol prior to mounting.
Normal colonic epithelium was used as positive control and adja-
cent normal gastric mucosa as internal control. Negative controls
included adjacent sections of the same block in which the primary
antibody was replaced by non-specific mouse IgG.
Interpretation of staining
Slides were independently examined by two experienced
observers (SR and JN) who were blinded to the stage of the tumour
and to the initial score of the other observer. The intensity (absent,
weak or strong) was scored in a semi-quantitative fashion graded
0–2, and pattern (membranous, cytoplasmic or nuclear) of staining
was recorded. In cases of heterogenous staining (more than 10%
variation) within the tumour, particularly related to variations in
the degree of differentiation, the score was based on the dominant
pattern. Where there were differences, a consensus decision on the
final score was reached after joint re-examination of the slides and
discussion.
Statistical methods
Associations between antigen expression and clinico-pathological
indices were examined using the c2 test. Survival curves were
computed as described by Kaplan and Meier; the log-rank test
was used to examine the difference between curves. A P-value
of < 0.05 was accepted as statistically significant. All statistical
analyses were performed using the StatView package (Abacus
Concepts, Berkley, CA, USA).
RESULTS
Control samples and normal mucosa
All colonic control samples and internal control normal adjacent
gastric mucosa showed intense membranous staining throughout
the epithelium (Figure 1A). Increased intensity of membranous
Table 1 Clinico-pathological data collected
Age
Sex
T stage
N stage
M stage
UICC stage
Histological grade
Lauren class
Disease free survival
Overall survival1394 S Ramesh et al
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staining was noted in the deeper parts of antral, body and cardiac
glands.
Carcinoma
Forty gastric cancers were studied by immunohistochemistry
[IHC; intestinal type, 28 (70%); diffuse, 12 (30%)] according to
Lauren classification of gastric cancer. Tumour differentiation was
graded into well- (n = 1, 2.5%), moderate (n = 19, 47.5%) and
poor (n = 20, 50%). For purposes of statistical analysis, well- and
moderately differentiated tumours were grouped together. All
diffuse cancers were classed as poorly differentiated.
Tumour staining vs histology
Membranous
Reduced or absent membranous expression of b-catenin was more
common than ectopic intracellular expression. Weak or absent
membranous b-catenin expression was found in 18 of 40 cases
(45%): ten of 12 (83.4%) diffuse and in eight of 28 (28.6%)
intestinal type cancers (P = 0.0014, see Figure 1B). In this series, no
difference between E-cadherin membranous staining patterns in the
two tumour types was found, with loss of membranous expression
of E-cadherin in nine of 12 (75%) diffuse cancers and in 21 of 28
(75%) intestinal type cancers (Figure 1c and Table 2). a-catenin
staining patterns equally were unrelated to tumour type, with loss of
membranous expression in 11 of 12 (91%) diffuse cancers and 22 of
28 (78.6%) of intestinal type cancers (results not shown).
Intracellular
Three of 12 diffuse tumours and ten of 28 intestinal tumours
showed strong cytoplasmic b-catenin staining. Four intestinal
tumours (Figure 1D) and one diffuse tumour showed strong
b-catenin nuclear staining. These differences were not statistically
significant. For neither E-cadherin nor a-catenin was there any
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Figure 1 Photomicrographs to show immunohistochemical staining patterns. (A) Normal gastric mucosa to show strong membranous b-catenin expression,
with no intracellular expression. (B) Absent membranous b-catenin expression in diffuse gastric cancer. (C) Absent membranous E-cadherin expression in
gastric cancer. (D) Strong nuclear b-catenin expression in intestinal type cancer
Table 2 Relationship between immunostaininga and histology
E-Cadherin b-catenin
Memb Cyto Nucl Memb Cyto Nucl
diff int diff int diff int diff int diff int diff int
Strong 3 7 2 9 0 0 2 20 3 10 1 4
W e a k 92 11 01 94 04 01 0 8 91 8 1 12 4
c2 P-value NS NS NS 0.0014 NS NS
Memb = membranous, cyto = cytoplasm, nucl = nuclear, diff = diffuse cancer, int = intestinal type cancer. aData for a-catenin not shown.b-catenin expression in gastric cancer 1395
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correlation between intracellular staining and tumour histology
(Table 2) (results for a-catenin not shown).
Tumour staining vs differentiation
Membranous
Abnormalities of membranous expression of b-catenin appeared to
be related to tumour grade. Loss of membranous expression was
seen in four of 20 moderately differentiated cancers but in 14
of 20 poorly differentiated cancers (P < 0.0015) (Table 3). For
E-cadherin and a-catenin there was no correlation between
membranous staining and degree of tumour differentiation
(Table 3) (results for a-catenin not shown).
Intracellular staining
Abnormalities of intracellular cytoplasmic expression of E-
cadherin correlated with tumour grade. Strong cytoplasmic
E-cadherin expression was found in nine of 20 moderately
differentiated tumours, compared to two of 20 poorly differen-
tiated tumours (P = 0.0132) (Table 3). Nuclear localization of
b-catenin was observed in three of 20 moderately differentiated,
compared to two of 20 poorly differentiated tumours. Nuclear
expression was not observed for E-cadherin or a-catenin
immunostaining.
Tumour staining vs nodal status
Lymph node status was categorized according to TNM rules
(Sobin and Wittekind, 1997). For purposes of statistical analysis
N2 and N3 were grouped together.
The relationship between N stage and expression of E-cadherin
and b-catenin molecules at the membrane and in cytoplasm is
shown in Table 4. Only the association between E-cadherin
membrane staining and nodal status was significant. Of 21 N2/3
stage tumours, 16 (76%) showed a loss of membranous E-cadherin
staining (P = 0.0199). Nuclear expression of b-catenin was seen in
Table 3 Relationship between immunostaininga and tumour differentiation
E-Cadherin b-catenin
Memb Cyto Nucl Memb Cyto Nucl
mod poor mod poor mod poor mod poor mod poor mod poor
Strong 7 3 9 2 0 0 16 6 8 5 3 2
Weak 13 17 11 18 40 40 4 14 12 15 17 18
c2 P-value NS 0.0132 NS 0.0015 NS NS
Memb = membranous, cyto = cytoplasm, nucl = nuclear, mod = moderately differentiated gastric carcinoma. aData for a-catenin not shown.
Table 4 Relationship between immunostaininga and nodal status
E-Cadherin b-catenin
Memb cyto Memb cyto
N0 N1 N2/3 N0 N1 N2/3 N0 N1 N2/3 N0 N1 N2/3
Strong 5 0 5515 67 1 0427
N e g 4 1 01 6 4 91 6 3 31 3 5 81 4
c2 P-value 0.0199 0.07 NS NS
Memb = membranous, cyto = cytoplasm, nucl = nuclear, neg = negative. aData for a-catenin not shown.
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Figure 2 (A) Kaplan–Meier survival curves showing a statistically significant survival advantage in tumours with strong membranous b-catenin expression
(thick line), compared with those that showed weak membranous expression (thin line). (B) Kaplan–Meier survival curves showing no differences in survival in
tumours showing strong cytoplasmic b-catenin expression (thick line), compared with those that showed weak cytoplasmic expression (thin line)1396 S Ramesh et al
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one patient with N0 nodal status, and two each of N1 and N2/3
status. For brevity, the nuclear expression is not shown in Table 4.
Survival analysis
Kaplan–Meier curves were computed to compare survival of
patients with normal versus reduced membranous expression, and
normal versus abnormal intracellular expression (both cytoplasmic
and nuclear) for each of the three molecules. Neither membranous
nor intracellular abnormalities of E-cadherin or a-catenin showed
any association with survival. The overall median survival of
patients in this study was 18.3 months (range 0.13–56.6). Median
survival for patients showing any abnormality of b-catenin expres-
sion (membranous or cytoplasmic) was 12.0 months. Median
survival was 30.0 months in the normal and 7.4 months in the
reduced membranous expression group. Loss of membranous
b-catenin expression was associated with significantly decreased
survival (P = 0.0319, Kaplan–Meier curves, Figure 2A). The
survival of patients with abnormal cytoplasmic (Figure 2B) or
nuclear expression of b-catenin was not significantly different
from that of patients without this abnormality.
DISCUSSION
Mutations affecting intercellular adhesion mechanisms have
emerged as important steps in the development and progression of
many human epithelial tumours. Loss of E-cadherin expression
correlates with advanced stage and high grade in cancers of the
breast (Oka et al, 1993), stomach (Shimoyama et al, 1991;
Matsuura et al, 1992), colorectum (Nigam et al, 1993), pancreas
(Pignatelli et al, 1994), bladder (Bringuier et al, 1993) and prostate
(Umbas et al, 1992).
In stomach cancer, mutations of the E-cadherin gene have been
reported in diffuse and histologically indeterminate tumours, but
seem rare in intestinal type cancer (Becker and Hofler, 1995). A
germline mutation in E-cadherin associated with familial gastric
cancer was recently reported in a New Zealand kindred (Guilford
et al, 1998). Mutations in a- and b-catenins have not been
convincingly demonstrated, but protein expression abnormalities
are relatively frequent, and occur in both diffuse and intestinal
cancers (Oka et al, 1992; Matsui et al, 1994; Jawhari et al, 1997).
We have confirmed a high frequency of expression abnormalities
for all three molecules studied. Analysis of the type of expression
revealed somewhat different patterns from previous reports,
which considered only global abnormality versus normality.
Surprisingly, E-cadherin expression overall did not correlate with
grade, although ectopic cytoplasmic expression of E-cadherin did.
b-catenin expression was closely related to tumour grade and
differentiation, loss of membranous expression occurring much
more frequently in poorly differentiated tumours. We found that
b-catenin but not a-catenin or E-cadherin expression abnormali-
ties were associated with poor survival, confirming the findings of
Jawhari et al (1997), but contradicting earlier reports (Yonemura
et al, 1995; Gabbert et al, 1996). Analysis of the type of expression
revealed that loss of membranous expression, rather than ectopic
cytoplasmic expression, was correlated with poor survival, the
opposite of the situation recently reported in colon cancer (Hugh
et al, 1999).
Abnormal protein expression of the components of the
cadherin–catenin complex may occur for a number of reasons.
Ectopic or reduced expression may occur directly because of
mutations in the gene concerned (Becker and Hofler, 1995), or
indirectly due to alterations in one of its partners in the complex
leading, for example, either to interference with the intermolecular
binding which anchors the protein in the complex (Kawanishi
et al, 1995; Streit et al, 1996) or altered transcription of their genes.
Abnormal expression of b-catenin can occur due to tyrosine
phosphorylation induced by activated growth factor receptors
(Shibamoto et al, 1994).
Given this complex picture, it is difficult to draw firm conclu-
sions about the specific molecular events which are occurring from
immunohistochemical studies alone. We found that loss of
membranous  b-catenin expression, but not gain of intracellular
expression, was significantly associated with poor survival.
Therefore dysfunction of the adhesion complex may influence
progression more than changes in signalling pathways brought
about by accumulation of intracellular b-catenin.
The importance of cadherins in mediating intercellular adhesion
suggests that loss of their function might promote invasion and
metastasis. Evidence for such a role has been provided by experi-
ments in vitro and in animal models (see above). Recently,
b-catenin has been shown to play a distinct and separate role in
intracellular signalling in which it complexes with the APC protein
(Rubinfeld et al, 1995), and thereby becomes degraded
(Munemitsu et al, 1995). Adenomas and carcinomas arising in
patients with familial polyposis carry APC mutations which
prevent binding and degradation of b-catenin, and in these
tumours, intracellular accumulation of the protein occurs (Inomata
et al, 1996). Free b-catenin binds the transcription factors Tcf and
Lef, assisting the up-regulation of transcription (Behrens et al,
1996; Korinek et al, 1997; Morin et al, 1997). Intense current
interest continues in the possibility that the tumour suppressor role
of APC may be mediated through its interaction with b-catenin,
which may thereby have an important role in signalling mecha-
nisms such as transduction of signals from the wnt-1 oncogene
(Hinck et al, 1994).
The differences between our findings in gastric cancer and those
reported by Hugh et al in colorectal cancer need to be confirmed in
a direct comparison, since they suggest that different mechanisms
may be important in progression in the two tumour types. This is
particularly interesting in view of the well known differences in
natural history between gastric and colonic cancer. Recurrence
after apparently curative resection is not uncommon in both
tumours, but the patterns of failure are strikingly different. In
colorectal cancer, isolated liver metastasis without evidence of
metastatic disease elsewhere occurs in about 25% of complete
resections (Welch and Donaldson, 1979), but this very rarely
happens in gastric cancer (Ochiai et al, 1994). We speculate that
ectopic expression of b-catenin may be associated with enhanced
blood-borne metastasis, whereas loss of membranous expression is
associated with enhanced local growth and spread. Further studies
are required to test the hypothesis that blood-borne metastasis is
associated with a particular type of b-catenin expression abnor-
mality.
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